Hani Gabra

Founder en Papyrus Therapeutics, Inc. .

Health Technology

Consumer Services

Commercial Services

Perfil

Hani Gabra is the founder of Papyrus Therapeutics, Inc. He is currently a Professor at Imperial College London.
He previously worked as the Director of Clinical Development at BerGenBio ASA from 2021 to 2022 and as the Vice President of Early Clinical Development at AstraZeneca PLC.

Cargos activos de Hani Gabra

Empresas	Cargo	Inicio
Imperial College London	Corporate Officer/Principal	-
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Founder	-

Todos los cargos activos de Hani Gabra

Antiguos cargos conocidos de Hani Gabra.

Empresas	Cargo	Fin
BERGENBIO ASA	Chief Tech/Sci/R&D Officer	-
ASTRAZENECA PLC	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Hani Gabra.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Hani Gabra.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
ASTRAZENECA PLC	Health Technology
BERGENBIO ASA	Health Technology

Empresas privadas	1
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Commercial Services